NASDAQ: CVKD
Cadrenal Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their CVKD stock forecasts and price targets.

Forecast return on equity

Is CVKD forecast to generate an efficient return?

Company
-53.31%
Industry
146.26%
Market
80.85%
CVKD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CVKD forecast to generate an efficient return on assets?

Company
-39.18%
Industry
36.38%
CVKD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CVKD earnings per share forecast

What is CVKD's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$4.61
Avg 2 year Forecast
-$2.75
Avg 3 year Forecast
-$1.57

CVKD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CVKD$16.78N/AN/A
INKT$7.86$19.50+148.09%Buy
KZR$4.39$9.00+105.01%Hold
ALGS$5.25$70.00+1,233.33%Buy
CASI$2.00$4.00+100.50%Buy

Cadrenal Therapeutics Stock Forecast FAQ

What is CVKD's earnings growth forecast for 2025-2027?

(NASDAQ: CVKD) Cadrenal Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Cadrenal Therapeutics's earnings in 2025 is -$10,651,368.On average, 3 Wall Street analysts forecast CVKD's earnings for 2025 to be -$8,671,666, with the lowest CVKD earnings forecast at -$10,827,130, and the highest CVKD earnings forecast at -$5,225,594. On average, 3 Wall Street analysts forecast CVKD's earnings for 2026 to be -$5,169,203, with the lowest CVKD earnings forecast at -$5,733,116, and the highest CVKD earnings forecast at -$4,135,362.

In 2027, CVKD is forecast to generate -$2,951,145 in earnings, with the lowest earnings forecast at -$2,951,145 and the highest earnings forecast at -$2,951,145.

If you're new to stock investing, here's how to buy Cadrenal Therapeutics stock.

What is CVKD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CVKD) forecast ROE is -53.31%, which is considered weak.

What is CVKD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CVKD) Cadrenal Therapeutics's current Earnings Per Share (EPS) is -$8.73. On average, analysts forecast that CVKD's EPS will be -$4.61 for 2025, with the lowest EPS forecast at -$5.76, and the highest EPS forecast at -$2.78. On average, analysts forecast that CVKD's EPS will be -$2.75 for 2026, with the lowest EPS forecast at -$3.05, and the highest EPS forecast at -$2.20. In 2027, CVKD's EPS is forecast to hit -$1.57 (min: -$1.57, max: -$1.57).

What is CVKD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CVKD) forecast ROA is -39.18%, which is lower than the forecast US Biotechnology industry average of 36.38%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.